查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1948948

2026-2032年全球伊卡替班醋酸鹽注射劑市場（依給藥途徑、最終用戶、製劑及給藥頻率分類）預測

Icatibant Acetate Injection Market by Administration Route, End User, Formulation, Dosing Frequency - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，醋酸伊卡替班注射液市值為 3.7218 億美元，預計到 2026 年將成長至 4.0131 億美元，到 2032 年將達到 6.3547 億美元，複合年成長率為 7.94%。

關鍵市場統計數據
基準年 2025 3.7218億美元
預計年份：2026年 4.0131億美元
預測年份 2032 6.3547億美元
複合年成長率 (%) 7.94%

本文策略性地介紹了臨床效用、給藥偏好以及不斷變化的醫療保健環境如何影響伊卡利班醋酸鹽注射液的市場定位。

在遺傳性血管性水腫的綜合治療中，伊卡他班醋酸鹽注射液已成為一種重要的治療手段，其優勢在於能夠快速控制症狀並提高治療的可及性。本文概述了該藥物的治療特性、劑量注意事項以及影響臨床和商業性決策的不斷發展的護理模式。透過重點介紹該藥物在急性發作控制中的作用及其在預防策略中的地位，讀者將了解其臨床效用以及影響其在不同醫療機構推廣應用的營運挑戰。

醫療服務模式、監管預期和通路的變化將如何重新定義醋酸艾替班注射液的取得和使用？

除了臨床療效之外，伊卡利班醋酸鹽注射液的治療格局正受到多種因素的共同影響，包括給藥模式、監管政策的演變以及患者自主權的提升。病患教育和居家照護能力的進步正促使治療從完全依賴醫院給藥轉向診所和家庭環境，進而影響製劑設計和訓練通訊協定。此外，人們越來越傾向於皮下注射而非侵入性更強的給藥途徑，並期望獲得更便捷、起效更快、症狀緩解更迅速的治療。

評估累積關稅措施和貿易政策調整對特種注射劑生產、供應鏈韌性和准入策略的影響

近期貿易政策的發展和關稅調整，為生物製藥和特殊注射劑的成本和物流挑戰帶來了新的複雜性。在此期間實施的美國關稅的累積影響，導致上游原料採購轉移，成品和組件進口成本上升，促使製造商重新評估其製造地並考慮供應商多元化策略。這些發展對價格談判、與經銷商的合約安排以及建構供應協議以降低未來政策變化風險都具有重要意義。

將適應症細微差別、給藥途徑、終端用戶環境、製劑選擇和分銷管道趨勢與策略定位聯繫起來的深度細分洞察

詳細的市場區隔框架闡明了治療價值的實現途徑，以及如何在臨床和分銷環境中最佳化商業性策略。就適應症而言，市場主要圍繞著遺傳性血管性水腫展開，並根據治療目的進一步細分：急性發作管理與預防性治療。這種區別決定了臨床通訊、給藥策略以及臨床醫生在按需治療和預防性治療之間進行選擇所需的證據類型。從給藥途徑來看，主要有兩種途徑：靜脈注射和皮下注射，每種途徑對訓練、給藥時間以及家庭或診所使用的適用性都有不同的影響。

區域因素（美洲、歐洲、中東和非洲地區、亞太地區）將決定准入途徑、分銷模式和市場接受度促進因素。

區域趨勢正在為伊卡利班醋酸酯注射劑的採納、報銷和供應鏈設計創造不同的環境，美洲、歐洲、中東和非洲以及亞太地區各自面臨著獨特的挑戰。在美洲，臨床醫生對標靶治療的接受度提高以及專科藥房服務的擴展，推動了人們對居家給藥和快速獲取途徑的廣泛關注。同時，支付方的談判往往側重於實際療效和利用管理。這種環境重視健全的病患支持計畫以及對急性醫療資源利用有明確影響的證據。

製藥公司、專業合作夥伴和服務供應商如何透過配方創新、證據產生和卓越的供應鏈管理來創造競爭優勢？

醋酸伊卡他班注射的競爭格局呈現出多元化的特點，既有原廠生物製藥公司，也有專科製藥公司、契約製造組織以及新興的生物相似藥或替代療法開發商。競爭差異化不再僅依賴分子療效，而是日益依賴製劑創新、給藥便利性、為患者和醫療服務提供者提供的支持服務以及供應鏈夥伴關係關係的穩固性等因素。在監管要求複雜的地區，策略聯盟、授權協議和共同開發契約是拓展地域覆蓋範圍和縮短產品上市時間的常用途徑。

制定切實可行的策略重點，將以患者為中心、實證醫學和供應鏈韌性相結合，以推動市場接受度並確保市場持續性。

為確保持續的可及性和應用，產業領導者應優先考慮一系列兼顧臨床價值和卓越營運的措施。首先，投資以病人為中心的給藥方案，實現微創給藥並支持居家照護，同時為看護者和臨床醫生提供全面的培訓資源。其次，建立強大的真實世界證據項目，收集實際臨床環境中的治療結果，加強與支付者的溝通，並展現超越臨床試驗終點的價值。這些數據資產的設計應同時支持衛生經濟學論述和臨床指引。

採用穩健的混合調查方法，整契約儕審查的證據、相關人員訪談和情境分析，以產生可操作的臨床和商業性見解。

本執行摘要的研究結合了結構化的二手資料研究、專家訪談和定性綜合分析，以確保對臨床、監管和商業性趨勢的全面觀點。二手資料包括同行評審文獻、監管指導文件、臨床實踐指南以及描述治療機制、劑量注意事項和安全性概況的已發表文件。對這些資料的審查旨在建立臨床背景基礎，並識別影響實際應用的政策和醫療服務的最新變化。

簡要結論總結了臨床特徵、交付創新和營運韌性如何共同決定未來治療方案採納的走向。

總之，醋酸伊卡利班注射液在遺傳性血管性水腫的治療中佔據著重要的戰略地位，其快速控制症狀和以患者主導的護理模式的進步指導著治療方案的選擇。給藥途徑、製劑形式和給藥頻率的相互作用決定了產品的供應地點和方式，而成功的商業化取決於將這些臨床特性與分銷能力和支付方的期望相匹配。不斷變化的貿易政策和日益多元化的分銷環境帶來的雙重壓力凸顯了製定整合策略的必要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依給藥途徑分類的伊卡替班醋酸鹽注射劑市場

  • 靜脈注射
  • 皮下注射

9. 依最終用戶分類的伊卡替班醋酸鹽注射液市場

  • 診所
  • 居家照護
  • 醫院

第10章 醋酸伊卡替班注射劑市場（以劑型分類）

  • 預填充式注射器
  • 單劑量管瓶

第11章 依給藥頻率分類的醋酸伊卡替班注射劑市場

  • 一經請求
  • 預防

第12章 伊卡替班醋酸鹽注射液市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 伊卡替班醋酸鹽注射液市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國伊卡替班醋酸鹽注射液市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國伊卡替班醋酸鹽注射劑市場

第16章 中國伊卡替班醋酸鹽注射液市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alembic Pharmaceuticals
  • AMBIOPHARM
  • Amneal Pharmaceuticals
  • Apotex Inc.
  • Aurobindo Pharma
  • Bachem
  • BCN Peptides
  • Biophore India
  • Caplin Steriles
  • Chengdu Shengnuo Biopharm
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Fresenius Kabi USA
  • Glenmark Pharmaceuticals
  • Hetero Healthcare
  • Jiangsu Hansoh Pharmaceutical Group
  • Lupin Limited
  • Mylan
  • Nang Kuang Pharmaceutical
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries
  • Wilshire Pharmaceuticals
Product Code: MRR-4F7A6D4FB900

The Icatibant Acetate Injection Market was valued at USD 372.18 million in 2025 and is projected to grow to USD 401.31 million in 2026, with a CAGR of 7.94%, reaching USD 635.47 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 372.18 million
Estimated Year [2026] USD 401.31 million
Forecast Year [2032] USD 635.47 million
CAGR (%) 7.94%

A strategic introduction to how clinical utility, administration preferences, and evolving care settings shape the positioning of icatibant acetate injection

Icatibant acetate injection has emerged as a focused therapeutic tool within the broader management paradigm for hereditary angioedema, where rapid symptom control and treatment accessibility are paramount. This introduction frames the therapeutic profile, administrative considerations, and evolving care models that shape clinical and commercial decision-making. By concentrating on the agent's role in acute attack management and its place within prophylactic strategies, readers can appreciate both its clinical utility and the operational challenges that influence adoption across care settings.

Clinical practice patterns show a growing emphasis on patient-centric delivery, including preferences that favor minimally invasive administration and settings that reduce time to treatment. As such, administration route and formulation choices directly influence how clinicians, payers, and patients perceive value. Concurrently, regulatory frameworks and reimbursement pathways for specialty injectables continue to evolve, compelling manufacturers and distributors to refine market access approaches and educational outreach for prescribers and caregivers.

Supply chain dynamics, manufacturing scalability, and the emergence of alternative formulations also feed into strategic planning for stakeholders across the value chain. Taken together, these factors create a complex landscape in which clinical efficacy, ease of use, and channel strategy determine real-world uptake. The introduction sets the stage for a deeper investigation into shifts in therapy delivery, policy impacts, segmentation nuances, regional heterogeneity, competitive behavior, and practical recommendations to inform near-term strategic choices.

How shifts in care delivery models, regulatory expectations, and distribution channels are redefining access and adoption of icatibant acetate injection

The therapeutic landscape for icatibant acetate injection is being reshaped by converging forces that extend beyond simple clinical efficacy to encompass delivery models, regulatory evolution, and patient empowerment. Advances in patient education and homecare capabilities have encouraged a migration of treatment from exclusive hospital administration toward clinic and home settings, which in turn is influencing formulation design and training protocols. Additionally, the preference for subcutaneous administration over more invasive routes has heightened expectations for convenience, rapid onset of effect, and reduced time to symptom relief.

At the same time, regulatory agencies are clarifying pathways for specialty injectables, emphasizing real-world evidence and post-marketing safety monitoring. These regulatory shifts are prompting manufacturers to invest in more robust data infrastructure and to design pharmacovigilance programs that support extended use beyond randomized controlled trial settings. Payer scrutiny is also intensifying, with reimbursement decisions increasingly tied to documented outcomes and cost-effectiveness in pragmatic care pathways rather than trial-based endpoints alone.

Commercially, distribution strategies are undergoing transformation as online pharmacy models and direct-to-patient channels gain traction alongside traditional hospital and retail pharmacy networks. This diversification requires integrated logistics approaches that preserve cold chain integrity, ensure traceability, and support rapid fulfillment to maintain treatment timeliness. Collectively, these shifts demand that stakeholders adopt more agile product strategies, align clinical messaging with real-world performance, and build scalable support services that meet the needs of patients, caregivers, and clinicians in a changing care environment.

Assessment of how cumulative tariff measures and trade policy adjustments are influencing manufacturing, supply chain resilience, and access strategies for specialty injectables

Recent trade policy developments and tariff adjustments have injected new layers of complexity into the cost and logistics equation for biologics and specialty injectables. The cumulative impact of United States tariff measures implemented in this period has altered upstream raw material sourcing, elevated import-related costs for finished products and components, and encouraged manufacturers to reassess manufacturing footprints and supplier diversification strategies. These dynamics have meaningful implications for pricing negotiations, contractual arrangements with distributors, and the structuring of supply agreements to mitigate exposure to future policy shifts.

Manufacturers and supply chain partners have responded by exploring nearshoring of production, qualifying alternate suppliers, and redesigning packaging and distribution to minimize tariff-sensitive components. Procurement teams are placing greater emphasis on total landed cost analysis rather than unit price alone, while commercial teams are preparing more nuanced pricing and access conversations with payers to reflect these added complexities. In parallel, service providers in logistics and customs brokerage are working to streamline clearance processes and to offer compliant, cost-efficient pathways for movement of temperature-controlled products.

It is also notable that tariff-driven cost pressures are accelerating conversations about strategic inventory placement and contractual flexibility. Organizations are increasingly modeling scenarios where supply disruptions or sudden cost escalations could affect channel availability and patient access. Consequently, cross-functional planning has become essential, weaving together regulatory, commercial, supply chain, and financial perspectives to preserve continuity of care while responding to externally driven cost volatility.

Deep segmentation insights that connect indication nuance, administration route, end user environments, formulation choices, and channel dynamics to strategic positioning

A granular segmentation framework provides clarity on where therapeutic value is realized and how commercial approaches should be tailored across clinical and distribution contexts. When considering indication, the market centers on hereditary angioedema, which is further differentiated by treatment intent between acute attack management and prophylaxis; this distinction informs clinical messaging, dosing strategies, and the kinds of evidence clinicians require to choose between on-demand therapy and preventive regimens. Looking at administration route, two primary pathways emerge: intravenous injection and subcutaneous injection, each presenting different implications for training, time to administration, and suitability for home or clinic use.

End user segmentation highlights the practical environments where treatment is delivered, spanning clinic, homecare, and hospital settings; each setting has distinct clinical workflows, procurement mechanisms, and reimbursement pathways that influence uptake. Distribution channel analysis identifies hospital pharmacy, online pharmacy, and retail pharmacy as the principal conduits to patients, with the online pharmacy channel itself subdivided into branded pharmacy and generic pharmacy models that affect pricing dynamics and patient choice. Formulation considerations further refine market positioning, with prefilled syringes and single dose vials offering trade-offs between convenience, waste, and perceived safety.

Finally, dosing frequency delineates opportunities between on-demand interventions and prophylactic strategies, shaping long-term patient support programs, adherence initiatives, and payer negotiations. Integrating these segmentation lenses enables stakeholders to align product development, clinical education, channel strategy, and access planning with the nuanced needs of prescribers and patients across different care pathways.

Regional considerations across the Americas, Europe Middle East & Africa, and Asia Pacific that determine access pathways, distribution models, and adoption drivers

Regional dynamics create distinct environments for adoption, reimbursement, and supply chain design, with the Americas, Europe, Middle East & Africa, and Asia-Pacific each presenting unique considerations for icatibant acetate injection. In the Americas, strong clinician familiarity with targeted therapies and the growth of specialty pharmacy services underpin broad interest in home administration and rapid access pathways, while payer negotiation tends to focus on real-world outcomes and utilization management. This environment rewards robust patient support programs and clear evidence of impact on acute care resource utilization.

In Europe, Middle East & Africa, the regulatory and reimbursement landscape is heterogeneous, necessitating tailored market access strategies that account for country-level health technology assessment practices and variable procurement processes. Centralized hospital channels remain influential in many markets, yet there is a growing appetite for decentralized care models that reduce hospital burden. Manufacturers must therefore navigate divergent pricing frameworks and demonstrate alignment with public health priorities.

Asia-Pacific features a mix of high-capacity healthcare systems and rapidly developing markets where access constraints and supply chain complexity may influence adoption timing. Local manufacturing partnerships and targeted educational initiatives are often critical for market entry and scale-up. Across all regions, logistical capabilities for temperature-controlled distribution, culturally appropriate patient education, and collaboration with specialty pharmacies or homecare providers are decisive factors in ensuring timely access and adherence.

How manufacturers, specialty partners, and service providers are shaping competitive advantage through formulation innovation, evidence generation, and supply chain excellence

The competitive landscape for icatibant acetate injection is characterized by a mix of originator biologic manufacturers, specialty pharmaceutical companies, contract manufacturing organizations, and emerging biosimilar or alternative therapeutic developers. Competitive differentiation increasingly hinges on more than molecule efficacy; it encompasses formulation innovation, ease of administration, support services for patients and providers, and the robustness of supply chain partnerships. Strategic alliances, licensing arrangements, and co-development agreements are common mechanisms for extending geographic reach and accelerating time to market in jurisdictions with complex regulatory requirements.

Manufacturers that invest in real-world evidence generation, targeted clinician education, and integrated patient support programs tend to achieve stronger engagement with prescribers and payers. Similarly, companies that develop streamlined reconstitution-free formulations, prefilled delivery systems, or other administration conveniences can reduce barriers to use in homecare and clinic settings. On the manufacturing side, scaling capacity for sterile injectables and maintaining rigorous quality systems are prerequisites for sustaining supply reliability, particularly where multi-country distribution is involved.

Service providers, including specialized distributors and temperature-controlled logistics partners, play an influential role in enabling market penetration. Their capabilities to offer traceability, cold chain assurance, and rapid fulfillment are often decisive in contracting conversations with hospital systems and specialty pharmacies. Overall, the competitive arena rewards integrated strategies that combine product-level advantages with superior operational execution and stakeholder engagement.

Actionable strategic priorities that align patient centricity, evidence generation, and supply chain resilience to accelerate adoption and secure market continuity

Industry leaders should prioritize a set of actions that align clinical value with operational excellence to secure sustained access and uptake. First, invest in patient-centric delivery options that favor minimally invasive administration and support home-based care, while also providing comprehensive training resources for caregivers and clinicians. Second, build robust real-world evidence programs that capture outcomes in pragmatic care settings to strengthen payer discussions and demonstrate value beyond clinical trial endpoints. These data assets should be designed to inform both health economic narratives and clinical guidelines.

Third, diversify supplier networks and evaluate manufacturing footprint adjustments to mitigate exposure to trade policy volatility and to shorten lead times. Strengthening contractual flexibility with logistics and distribution partners can preserve continuity of supply under varying trade or tariff scenarios. Fourth, tailor market access strategies to regional and local payer expectations by combining centralized evidence packages with country-specific health economic analyses and stakeholder engagement plans. Fifth, consider enhanced digital engagement and telehealth integrations to improve time to treatment and follow-up adherence, which in turn supports better outcomes and more favorable payer conversations.

Finally, align internal cross-functional decision-making processes to ensure that regulatory, commercial, supply chain, and medical affairs teams operate on shared priorities. This integrated approach reduces the risk of misaligned launches and enables faster adaptation to regulatory or market shifts. Executed together, these actions will help companies translate scientific promise into sustained clinical adoption and operational resilience.

A robust mixed methodology that integrates peer reviewed evidence, stakeholder interviews, and scenario analysis to produce actionable clinical and commercial insights

The research underpinning this executive summary combines structured secondary research, expert interviews, and qualitative synthesis to ensure a comprehensive view of clinical, regulatory, and commercial dynamics. Secondary sources included peer-reviewed literature, regulatory guidance documents, clinical practice guidelines, and public filings that describe therapeutic mechanisms, administration considerations, and safety profiles. These materials were reviewed to establish baseline clinical context and to identify recent changes in policy and care delivery that influence real-world use.

Primary insights were derived from interviews with clinicians, pharmacy directors, supply chain executives, and market access professionals who provided frontline perspectives on prescribing behavior, channel preferences, and logistical constraints. Interview inputs were analyzed alongside publicly available regulatory decisions and reimbursement trends to triangulate findings and to surface practical implications for strategy and operations. The synthesis emphasized recurring themes across stakeholders, such as the importance of administration route, homecare enablement, and the need for pragmatic evidence to support payer engagement.

Where appropriate, scenario analysis was applied to examine the implications of supply chain disruptions and tariff-driven cost shifts on procurement and distribution strategies. The methodological approach prioritized transparency in assumptions and sought to present actionable insight rather than speculative projections, ensuring that readers receive practical guidance grounded in current clinical practice and commercial realities.

A concise conclusion summarizing how clinical attributes, delivery innovation, and operational resilience together determine the future trajectory of therapeutic adoption

In conclusion, icatibant acetate injection occupies a strategic niche in the management of hereditary angioedema, where rapid symptom control and increasingly patient-directed care models are guiding therapeutic choices. The interplay between administration route, formulation, and dosing frequency shapes where and how the product is delivered, and successful commercialization depends on aligning these clinical attributes with distribution capabilities and payer expectations. Concurrent pressures from evolving trade policies and a diversifying distribution landscape underscore the need for integrated strategies that balance clinical value with operational resilience.

Organizations that combine formulation and delivery innovation with robust real-world evidence, flexible supply chain arrangements, and targeted regional market access plans will be best positioned to respond to changing care models and policy environments. Cross-functional coordination and proactive stakeholder engagement remain essential to translating clinical benefits into routine practice. The landscape will continue to evolve as new delivery paradigms, regulatory clarifications, and distribution innovations emerge, and staying attuned to these developments will be critical for sustained success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Icatibant Acetate Injection Market, by Administration Route

  • 8.1. Intravenous Injection
  • 8.2. Subcutaneous Injection

9. Icatibant Acetate Injection Market, by End User

  • 9.1. Clinic
  • 9.2. Homecare
  • 9.3. Hospital

10. Icatibant Acetate Injection Market, by Formulation

  • 10.1. Prefilled Syringe
  • 10.2. Single Dose Vial

11. Icatibant Acetate Injection Market, by Dosing Frequency

  • 11.1. On-Demand
  • 11.2. Prophylactic

12. Icatibant Acetate Injection Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Icatibant Acetate Injection Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Icatibant Acetate Injection Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Icatibant Acetate Injection Market

16. China Icatibant Acetate Injection Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alembic Pharmaceuticals
  • 17.6. AMBIOPHARM
  • 17.7. Amneal Pharmaceuticals
  • 17.8. Apotex Inc.
  • 17.9. Aurobindo Pharma
  • 17.10. Bachem
  • 17.11. BCN Peptides
  • 17.12. Biophore India
  • 17.13. Caplin Steriles
  • 17.14. Chengdu Shengnuo Biopharm
  • 17.15. Cipla Limited
  • 17.16. Dr. Reddy's Laboratories
  • 17.17. Fresenius Kabi USA
  • 17.18. Glenmark Pharmaceuticals
  • 17.19. Hetero Healthcare
  • 17.20. Jiangsu Hansoh Pharmaceutical Group
  • 17.21. Lupin Limited
  • 17.22. Mylan
  • 17.23. Nang Kuang Pharmaceutical
  • 17.24. Sun Pharmaceutical Industries
  • 17.25. Takeda Pharmaceutical Company
  • 17.26. Teva Pharmaceutical Industries
  • 17.27. Wilshire Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ICATIBANT ACETATE INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ICATIBANT ACETATE INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ICATIBANT ACETATE INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ICATIBANT ACETATE INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. AMERICAS ICATIBANT ACETATE INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 35. AMERICAS ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 36. AMERICAS ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 39. NORTH AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. NORTH AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 41. NORTH AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 44. LATIN AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. LATIN AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 46. LATIN AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. EUROPE, MIDDLE EAST & AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASEAN ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 77. ASEAN ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 80. GCC ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GCC ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 82. GCC ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GCC ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. GCC ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPEAN UNION ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPEAN UNION ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPEAN UNION ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 90. BRICS ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. BRICS ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 92. BRICS ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 95. G7 ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. G7 ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. G7 ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. G7 ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. G7 ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 100. NATO ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NATO ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 102. NATO ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NATO ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 104. NATO ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ICATIBANT ACETATE INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. UNITED STATES ICATIBANT ACETATE INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. UNITED STATES ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 108. UNITED STATES ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 111. CHINA ICATIBANT ACETATE INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 112. CHINA ICATIBANT ACETATE INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 113. CHINA ICATIBANT ACETATE INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA ICATIBANT ACETATE INJECTION MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA ICATIBANT ACETATE INJECTION MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)